Jeremy Slade Abramson MD

Oncology•Boston, MA

Hematologic Oncology

Center for Lymphoma, Massachusetts General Hospital Cancer Center

Join to View Full Profile

55 Fruit St# MghBoston, MA 02114
Phone+1 617-724-4000
Fax+1 617-643-1915

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Icahn School of Medicine at Mount SinaiClass of 2000

Certifications & Licensure

MA State Medical License 2002 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry

Clinical Trials

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas Start of enrollment: 2009 Jul 01
Completed
Phase 2
Bortezomib Plus Rituximab for EBV+ PTLD Start of enrollment: 2011 Nov 01
Completed
Phase 2
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Start of enrollment: 2010 Dec 01
Completed
Phase 2
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL Start of enrollment: 2012 Dec 01
Completed
Phase 1
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2013 Jul 01
Terminated
Early Phase 1
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Start of enrollment: 2013 Sep 05
Completed
Phase 1
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Start of enrollment: 2014 Oct 01
Completed
Phase 1
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
ACTIVE_NOT_RECRUITING
PHASE2
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma Start of enrollment: 2015 Aug 07
Completed
Phase 2
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
ACTIVE_NOT_RECRUITING
PHASE1
Pembrolizumab in Neoplasms or Lymphomas Start of enrollment: 2017 Dec 07
SUSPENDED
PHASE2
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Start of enrollment: 2021 Jun 04
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

KR-acking the code in non-GCB DLBCL?
Adrian Minson, Jeremy Abramson
Leukemia & Lymphoma. 2025-08-03
Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Ly...
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, Jennifer R Brown, Mazyar Shadman
Transplantation and Cellular Therapy. 2025-08-01
Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractor...
Jeremy S Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali
Leukemia & Lymphoma. 2025-07-24

Abstracts/Posters

High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements o...
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial re...
2019 ASCO Annual Meeting - 6/1/2019
Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene mara...
2019 ASCO Annual Meeting - 6/1/2019
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

$Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People with Relapsed or Refractory Diffuse Large B-cell Lymphoma$
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People with Relapsed or Refractory Diffuse Large B-cell LymphomaJuly 18th, 2025
$Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL$
Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCLDecember 6th, 2024
Transplant vs. CAR T in DLBCL: Not Always an Either/Or QuestionOctober 21st, 2022
Join now to see all